Fate Therapeutics, Juno Therapeutics deal

Fate granted Juno worldwide rights to develop and commercialize engineered T cell immunotherapies for cancer using Fate’s small molecule modulators. Fate will screen its library of small molecules to seek modulators that can enhance the activity of Juno’s chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies. Fate said the goal of the deal is to improve the potency, persistence, proliferation and homing of Juno’s T cell therapies. Fate’s small molecules regulate undisclosed proteins on the surface of cells. ...